Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Mythri Mudireddy"'
Publikováno v:
Uro, Vol 3, Iss 2, Pp 117-131 (2023)
Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last several years, ad
Externí odkaz:
https://doaj.org/article/310e1028ccac405dbbac207fef575e58
Publikováno v:
Therapeutic Advances in Urology, Vol 15 (2023)
Maintenance therapy with immune checkpoint inhibitors (ICIs) has changed the treatment paradigm of metastatic urothelial carcinoma (mUC). The JAVELIN Bladder 100 trial established avelumab, one of several ICIs in use today, as a life-prolonging maint
Externí odkaz:
https://doaj.org/article/c66434ef54354f5191dcc85a3254ee22
Autor:
Ayalew Tefferi, Maura Nicolosi, Domenico Penna, Mythri Mudireddy, Natasha Szuber, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh D. Pardanani
Publikováno v:
Blood Advances, Vol 2, Iss 15, Pp 1980-1984 (2018)
Externí odkaz:
https://doaj.org/article/227de734e2e349a6acb62355f32868fa
Autor:
Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi
Publikováno v:
Blood Advances, Vol 2, Iss 4, Pp 370-380 (2018)
Abstract: Among 248 consecutive patients with blast phase myeloproliferative neoplasm (MPN-BP), DNA collected at the time of blast transformation was available in 75 patients (median age, 66 years; 64% men). MPN-BP followed primary myelofibrosis in 3
Externí odkaz:
https://doaj.org/article/b5d356f11b494dfc9a722ce111424a3c
Autor:
Christy Finke, Curtis A. Hanson, Mythri Mudireddy, Ayalew Tefferi, Terra L. Lasho, Naseema Gangat, Animesh Pardanani, Rhett P. Ketterling
Publikováno v:
American Journal of Hematology. 94:299-305
JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. In 2010, we reported an association between shortened survival in primary myelofibrosis (PMF) and nullizygosity for the JAK2 46/1 haplotype.
Autor:
Michelle A. Elliott, Chien-Chin Lin, Mark R. Litzow, Hsin-An Hou, Ayalew Tefferi, Mrinal M. Patnaik, Rhett P. Ketterling, Rong He, Kebede H. Begna, David S. Viswanatha, Curtis A. Hanson, Mythri Mudireddy, Animesh Pardanani, Hwei-Fang Tien, Naseema Gangat, C. Christopher Hook, Aref Al-Kali, Alexandra P. Wolanskyj, Jih-Luh Tang, Cheng-Hong Tsai, Darci Zblewski, William J. Hogan, Terra L. Lasho, Wen-Chien Chou, Christy Finke
Publikováno v:
Mayo Clinic Proceedings. 93:1363-1374
Objective To develop a new risk model for primary myelodysplastic syndromes (MDS) that integrates information on mutations, karyotype, and clinical variables. Patients and Methods Patients with World Health Organization–defined primary MDS seen at
Autor:
Christy Finke, Ayalew Tefferi, Naseema Gangat, Mythri Mudireddy, Rhett P. Ketterling, Terra L. Lasho, Curtis A. Hanson, Animesh Pardanani, Aneel A. Ashrani, David M. Nagorney
Publikováno v:
American Journal of Hematology. 93:E235-E238
Autor:
Ayalew Tefferi, Christy Finke, Animesh Pardanani, Mythri Mudireddy, Terra L. Lasho, Natasha Szuber, Curtis A. Hanson, Kebede H. Begna, Naseema Gangat, Rhett P. Ketterling, Mrinal M. Patnaik
Publikováno v:
Blood Advances. 2:370-380
Among 248 consecutive patients with blast phase myeloproliferative neoplasm (MPN-BP), DNA collected at the time of blast transformation was available in 75 patients (median age, 66 years; 64% men). MPN-BP followed primary myelofibrosis in 39 patients
Autor:
Tiziano Barbui, Curtis A. Hanson, Ayalew Tefferi, Maura Nicolosi, Mario Cazzola, Francesco Passamonti, Francesco Mannelli, Animesh Pardanani, Alessandro M. Vannucchi, Giada Rotunno, Annalisa Pacilli, Naseema Gangat, Elisa Rumi, Paola Guglielmelli, Vittorio Rosti, Carmela Mannarelli, Rhett P. Ketterling, Terra L. Lasho, Giovanni Barosi, Mythri Mudireddy, Alessandro Rambaldi
Publikováno v:
Journal of Clinical Oncology. 36:310-318
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and Methods The study included 805 patients with PMF age ≤ 70 years recruite
Autor:
Mythri Mudireddy, Terra L. Lasho, Kebede H. Begna, Ayalew Tefferi, Animesh Pardanani, Rhett P. Ketterling, Naseema Gangat, Curtis A. Hanson, Maura Nicolosi
Publikováno v:
Leukemia
Current cytogenetic risk stratification in primary myelofibrosis (PMF) is two-tiered: ‘favorable’ and ‘unfavorable’. Recent studies have suggested prognostic heterogeneity within the unfavorable risk category. In 1002 consecutive patients, we